7:30am  NETWORKING BREAKFAST

8:00am  WELCOME
Jim Palma
CEO, TargetCancer Foundation

8:30am  PATIENT KEYNOTE
Zebracorn: A Rare Patient’s Story
Katie Doble

8:55am  SCIENTIFIC KEYNOTE
Future-Proofing Healthcare: A Vision of Patient-Centric Tissue-Agnostic Precision Medicine
Vivek Subbiah, MD  
Chief, Early-Phase Drug Development, Sarah Cannon Research Institute

9:30am  SESSION 1: CLINICAL TRIALS IN RARE CANCERS
On The Right TRACK- A National Decentralized Precision Genomics Trial for Rare Cancers
Razelle Kurzrock, MD
Professor of Medicine; Associate Director, Clinical Research
Founding Director, Michels Rare Cancers Research Laboratories
Froedtert and Medical College of Wisconsin

Innovative Immunotherapy Basket Trial Experience with the NCI-SWOG DART Trial
Young Kwang Chae, MD, MPH, MBA
Co-Director, Early Phase Clinical Trials Unit, Lurie Cancer Center
Associate Professor, Department of Medicine, Northwestern University Feinberg School of Medicine

10:35am  MORNING BREAK

10:55am  SESSION 2: HEREDITARY/GERMLINE GENETICS
The Role of Hereditary Cancer Predisposition in Precision Medicine
Catherine Skefos, MA, MS, CGC
Genetic Counselor, MD Anderson Cancer Center

Evaluation of TP53 Variants Detected on Hereditary Cancer Genetic Testing
Alison Schwartz Levine, MS, CGC
Genetic Counselor, Dana-Farber Cancer Institute

12:00pm  NETWORKING LUNCH
1:00pm **MOLECULAR TUMOR BOARD**
TCF-001 TRACK MOLECULAR TUMOR BOARD
Razelle Kurzrock, MD, Froedtert and Medical College of Wisconsin
Vivek Subbiah, MD, Sarah Cannon Research Institute
Jacob Adashek, DO, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Julia Elvin, MD, PhD, Foundation Medicine
Mina Nikanjam, MD, PhD, University of California San Diego
Catherine Skefos, MA, MS, CGC, MD Anderson Cancer Center

2:00pm **SESSION 3: TUMOR AGNOSTIC THERAPIES AT 5 YEARS**
Vitrakvi at 5 Years Following US Approval
Iain Webb, MD
Vice President, Head US Medical Affairs, Oncology, Bayer

Challenges in Implementation of Precision Oncology: Clinical Trials and Rare Tumors
Apostolia-Maria Tsimberidou, MD, PhD, FASCO, FAAAS
Professor, Department of Investigational Cancer Therapeutics
Katherine Russell Dixie Distinguished Endowed Professor
MD Anderson Cancer Center

FDA Perspective on Tissue Agnostic Cancer Drug Development
Martha Donoghue, MD
Associate Director, Pediatric Oncology and Rare Cancers, Oncology Center of Excellence, FDA

3:30pm **AFTERNOON BREAK**

4:00pm **PANEL AND GUIDED DISCUSSION**
Broader Distribution of Genomics and Clinical Trials to Underserved Communities
Olalekan Ajayi, PharmD, MBA
Chief Operating Officer, Highlands Oncology Group
President, Association of Community Cancer Centers (ACCC)

Jennifer Levin Carter, MD, MPH, MBA
Venture Partner, Sandbox Industries
Founder and CEO, Medzown, Inc.

Matthew Kulke, MD
Chief of Hematology/Oncology, Boston Medical Center
Co-Director, BU/BMC Cancer Center

Jens Rueter, MD
Chief Medical Officer, The Jackson Laboratory
Medical Director, Maine Cancer Genomics Initiative

5:00pm **COCKTAILS AND DINNER**

targetcancerfoundation.org/thinktank
# 2023 Think Tank on Advancing Precision Medicine in Rare Cancers

## Steering Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Affiliation</th>
</tr>
</thead>
</table>
| Jennifer Carter, MD, MPH, MBA | Venture Partner, Sandbox Industries  
 Founder and CEO, Medzown, Inc.                                                   |
| A. John Iafrate, MD, PhD     | Deputy Chair of Pathology, Massachusetts General Hospital  
 Professor of Pathology, Harvard Medical School                                      |
| Razelle Kurzrock, MD         | Professor of Medicine; Associate Director, Clinical Research  
 Founding Director, Michels Rare Cancers Research Laboratories  
 Froedttert and Medical College of Wisconsin  
 Principal Investigator, TCF-001 TRACK Study                                       |